VRTX-531 demonstrates best-in-class USP1 inhibitor activity in preclinical models

Nov. 5, 2024

Researchers from Vrise Therapeutics Inc. and Vegen Therapeutics Pvt Ltd. presented preclinical data for VRTX-531, an allosteric inhibitor of ubiquitin carboxyl-terminal hydrolase 1 (USP1), being developed for the treatment of cancer.

BioWorld Science Conferences AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Cancer

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for February 3, 2025

Vilastobart set apart? Xilio phase II combo performs in CRC

BioWorld

“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...

Novo weight-loss data roll out; Veru ‘leans’ in

BioWorld

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line...

Appointments and advancements for Jan. 29, 2025

BioWorld

New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock.

PFA update: Abbott to launch in EU, J&J hold indefinite

BioWorld MedTech

A pair of investor calls on Jan. 22 added clarity to the rapidly evolving cardiac ablation market with Abbott Laboratories and Johnson & Johnson providing updates...